Pfizer Receives Positive CHMP Opinion for Oncology Biosimilar, RUXIENCE
February 01, 2020
February 01, 2020
NEW YORK, Feb. 1 -- Pfizer, a pharmaceutical company, issued the following news release:
Pfizer Inc. (NYSE: PFE) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending marketing authorization for RUXIENCE(TM) (rituximab),1 a potential biosimilar to MabThera(R) (rituximab).2,3 RUXIENCE is a monoclonal antibody (mAb) for the treatment of non-Hodgkin's lymphoma (NHL), chronic lymphocyt . . .
Pfizer Inc. (NYSE: PFE) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending marketing authorization for RUXIENCE(TM) (rituximab),1 a potential biosimilar to MabThera(R) (rituximab).2,3 RUXIENCE is a monoclonal antibody (mAb) for the treatment of non-Hodgkin's lymphoma (NHL), chronic lymphocyt . . .